IBSA will participate in CPhI Japan 2025, showcasing cutting-edge pharmaceutical solutions and strengthening partnerships in the Asia-Pacific market. Key products on display include Sinovial® HL, Sinogel®, Ditralia®, Ialuril® Prefill, Hyaluxelle®, Me
IBSA’s HA-based viscosupplementation treatments offer effective relief for osteoarthritis, reducing pain and improving mobility. SINOVIAL® HL and SINOGEL®, powered by NAHYCO® HYBRID TECHNOLOGY, restore joint function and delay surgical interventions,
Osteoarthritis is the leading cause of musculoskeletal disability and a major burden on global public health. For the treatment of this disease IBSA has developed SINOVIAL® HL and SINOGEL®, two viscosupplementation products based on the NAHYCO® HYBRI
At the CPhI Worldwide IBSA presents its innovative solutions for the pharmaceutical market, looking for strategic licensing out agreements in countries where it does not operate directly and puts itself forward as a partner for CDMO projects in …
IBSA Institute Biochimique SA is pleased to announce that it has signed a collaboration agreement with Choose Life Biotech (CLB) to investigate innovative and cutting-edge areas of pharmaceutical research projects.
IBSA Institut Biochimique SA, the multinational pharmaceutical company based in Lugano, acquired 100% of the share capital of its UK distributor, Pharmasure Ltd.
